Immunogenicity and safety of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines in Taiwan

Journal of the Formosan Medical Association

Volumn 111, Issue 9, 2012, Pages 495-503

  Lin, Tzou Yien ^a   Lu, Chun Yi ^b   Chang, Luan Yin ^b   Chiu, Cheng Hsun ^a   Huang, Yhu Chering ^a   Bock, Hans L ^c   Tang, Haiwen ^d   François, Nancy ^c   Moreira, Marta ^c   Schuerman, Lode ^c   Huang, Li Min ^b  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^d GLAXOSMITHKLINE   (China)

Author keywords

Antibody response; Pneumococcal conjugate vaccine; Safety; Taiwan

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; PNEUMOCOCCUS VACCINE; ROTAVIRUS VACCINE;

ANOREXIA; ARTICLE; ATOPIC DERMATITIS; BRONCHITIS; DIARRHEA; DIPHTHERIA; DROWSINESS; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HAEMOPHILUS INFECTION; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; INJECTION SITE PAIN; INJECTION SITE SWELLING; IRRITABILITY; MALE; OPEN STUDY; PERTUSSIS; PNEUMOCOCCAL INFECTION; POLIOMYELITIS; ROTAVIRUS INFECTION; SEROTYPE; SIDE EFFECT; SKIN ALLERGY; SKIN REDNESS; TAIWAN; TETANUS; UPPER RESPIRATORY TRACT INFECTION; VACCINATION; VOMITING;

BACTERIAL CAPSULES; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS VACCINES; HUMANS; INFANT; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; TAIWAN; VACCINES, CONJUGATE;

EID: 84867007168     PISSN: None     EISSN: 09296646     Source Type: Journal    
DOI: 10.1016/j.jfma.2011.07.014     Document Type: Article

References (40)

1. World Health Organization Pneumococcal conjugate vaccine for childhood immunization - WHO position paper. Wkly Epidemiol Rec 2007, 82:93-104.
2. Van Bambeke F., Reinert R.R., Appelbaum P.C., Tulkens P.M., Peetermans W.E. Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options. Drugs 2007, 67:2355-2382.
3. Hsieh Y.C., Chang K.Y., Huang Y.C., Lin H.C., Ho Y.H., Huang L.M., et al. Clonal spread of highly beta-lactam-resistant Streptococcus pneumoniae isolates in Taiwan. Antimicrob Agents Chemother 2008, 52:2266-2269.
4. Jean S.S., Hsueh P.R., Lee W.S., Chang H.T., Chou M.Y., Chen I.S., et al. Nationwide surveillance of antimicrobial resistance among Haemophilus influenzae and Streptococcus pneumoniae in intensive care units in Taiwan. Eur J Clin Microbiol Infect Dis 2009, 28:1013-1017.
5. Chen C.J., Lin C.L., Chen Y.C., Wang C.W., Chiu C.H., Lin T.Y., et al. Host and microbiologic factors associated with mortality in Taiwanese children with invasive pneumococcal diseases, 2001 to 2006. Diagn Microbiol Infect Dis 2009, 63:194-200.
6. Siu L.K., Chu M.L., Ho M., Lee Y.S., Wang C.C. Epidemiology of invasive pneumococcal infection in Taiwan: antibiotic resistance, serogroup distribution, and ribotypes analyses. Microb Drug Resist 2002, 8:201-208.
7. Lo W.T., Wang C.C., Yu C.M., Chu M.L. Rate of nasopharyngeal carriage, antimicrobial resistance and serotype of Streptococcus pneumoniae among children in northern Taiwan. J Microbiol Immunol Infect 2003, 36:175-181.
8. Lauderdale T.L., Lee W.Y., Cheng M.F., Huang I.F., Lin Y.C., Hseih K.S., et al. High carriage rate of high-level penicillin-resistant Streptococcus pneumoniae in a Taiwan kindergarten associated with a case of pneumococcal meningitis. BMC Infect Dis 2005, 5:96.
9. Chen C.J., Huang Y.C., Su L.H., Lin T.Y. Nasal carriage of Streptococcus pneumoniae in healthy children and adults in northern Taiwan. Diagn Microbiol Infect Dis 2007, 59:265-269.
10. Dagan R., Poolman J., Siegrist C.A. Glycoconjugate vaccines and immune interference: A review. Vaccine 2010, 28:5513-5523.
11. Bakaletz L.O., Kennedy B.J., Novotny L.A., Duquesne G., Cohen J., Lobet Y. Protection against development of otitis media induced by nontypeable Haemophilus influenzae by both active and passive immunization in a chinchilla model of virus-bacterium superinfection. Infect Immun 1999, 67:2746-2762.
12. Prymula R., Peeters P., Chrobok V., Kriz P., Novakova E., Kaliskova E., et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006, 367:740-748.
13. Lagos R.M., Munoz A.E., Levine M.M., Lepetic A., Francois N., Yarzabal J.P., et al. Safety and immunogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Chilean children. Hum Vaccin 2011, 7:511-522.
14. Bermal N., Szenborn L., Chrobot A., Alberto E., Lommel P., Gatchalian S., et al. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity. Pediatr Infect Dis J 2009, 28:S89-S96.
15. Chevallier B., Vesikari T., Brzostek J., Knuf M., Bermal N., Aristegui J., et al. Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines. Pediatr Infect Dis J. 2009, 28:S109-S118.
16. Vesikari T., Wysocki J., Chevallier B., Karvonen A., Czajka H., Arsène J.P., et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 2009, 28:S66-S76.
17. Wysocki J., Tejedor J.C., Grunert D., Konior R., Garcia-Sicilia J., Knuf M., et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different Neisseria meningitidis serogroup C conjugate vaccines. Pediatr Infect Dis J 2009, 28:S77-S88.
18. Prymula R., Siegrist C.A., Chlibek R., Zemlickova H., Vackova M., Smetana J., et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet 2009, 374:1339-1350.
19. Silfverdal S.A., Hogh B., Bergsaker M.R., Skerlikova H., Lommel P., Borys D., et al. Immunogenicity of a 2-dose priming and booster vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine. Pediatr Infect Dis J 2009, 28:e276-e282.
20. Vesikari T., Karvonen A., Lindblad N., Korhonen T., Lommel P., Willems P., et al. Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months. Pediatr Infect Dis J 2010, 29:e47-e56.
21. Concepcion N.F., Frasch C.E. Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2001, 8:266-272.
22. Henckaerts I., Goldblatt D., Ashton L., Poolman J. Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. Clin Vaccine Immunol 2006, 13:356-360.
23. Poolman J.T., Frasch C.E., Kayhty H., Lestrate P., Madhi S.A., Henckaerts I. Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines. Clin Vaccine Immunol 2010, 17:134-142.
24. Jodar L., Butler J., Carlone G., Dagan R., Goldblatt D., et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 2003, 21:3265-3272.
25. World Health Organization (WHO) Recommendations for the production and control of pneumococcal conjugate vaccines 2005, Report No.: 927.
26. Romero-Steiner S., Libutti D., Pais L.B., Dykes J., Anderson P., Whitin J.C., et al. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol 1997, 4:415-422.
27. Henckaerts I., Durant N., De Grave D., Schuerman L., Poolman J. Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children. Vaccine 2007, 25:2518-2527.
28. Eskola J., Kilpi T., Palmu A., Jokinen J., Haapakoski J., Herva E., et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001, 344:403-409.
29. Kilpi T., Ahman H., Jokinen J., Lankinen K.S., Palmu A., Savolainen H., et al. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clin Infect Dis 2003, 37:1155-1164.
30. Lucero M.G., Nohynek H., Williams G., Tallo V., Simoes E.A., Lupisan S., et al. Efficacy of an 11-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia among children less than 2 years of age in the Philippines: a randomized, double-blind, placebo-controlled trial. Pediatr Infect Dis J 2009, 28:455-462.
31. Puumalainen T., Dagan R., Wuorimaa T., Zeta-Capeding R., Lucero M., Ollgren J., et al. Greater antibody responses to an eleven valent mixed carrier diphtheria- or tetanus-conjugated pneumococcal vaccine in Filipino than in Finnish or Israeli infants. Pediatr Infect Dis J 2003, 22:141-149.
32. Shao P.L., Lu C.Y., Chang L.Y., Huang F.Y., Wang C.Y., Yang C.Y., et al. Safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in Taiwanese infants. J Formos Med Assoc 2004, 103:613-617.
33. Wang C.C., Kuo H.Y., Chiang D.H., Tsai C.C., Lin M.L., Chan Y.L., et al. Invasive Haemophilus influenzae disease in adults in Taiwan. J Microbiol Immunol Infect 2008, 41:209-214.
34. Wang S.R., Lo W.T., Chou C.Y., Chen Y.Y., Tsai S.Y., Chu M.L., et al. Low rate of nasopharyngeal carriage and high rate of ampicillin resistance for Haemophilus influenzae among healthy children younger than 5 years old in northern Taiwan. J Microbiol Immunol Infect 2008, 41:32-40.
35. Leibovitz E., Jacobs M.R., Dagan R. Haemophilus influenzae: a significant pathogen in acute otitis media. Pediatr Infect Dis J 2004, 23:1142-1152.
36. Knuf M., Szenborn L., Moro M., Petit C., Bermal N., Bernard L., et al. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Pediatr Infect Dis J 2009, 28:S97-S108.
37. Zepp F., Schmitt H.J., Cleerbout J., Verstraeten T., Schuerman L., Jacquet J.M. Review of 8 years of experience with Infanrix hexa (DTPa-HBV-IPV/Hib hexavalent vaccine). Expert Rev Vaccines 2009, 8:663-678.
38. McCormack P.L., Keam S.J. Rotavirus vaccine RIX4414 (Rotarix): a review of its use in the prevention of rotavirus gastroenteritis. Paediatr Drugs 2009, 11:75-88.
39. Hoppenbrouwers K., Lagos R., Swennen B., Ethevenaux C., Knops J., Levine M.M., et al. Safety and immunogenicity of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-pertussis (DTP) combination vaccine administered in a dual-chamber syringe to infants in Belgium and Chile. Vaccine 1998, 16:921-927.
40. Lagos R., Hoffenbach A., Scemama M., Dupuy M., Schodel F., Hessel L., et al. Lot-to-lot consistency of a combined hexavalent diphtheria-tetanus-acellular-pertussis, hepatitis B, inactivated polio and Haemophilus B conjugate vaccine, administered to healthy Chilean infants at two, four and six months of age. Hum Vaccin 2005, 1:112-117.